Glaukos Co. (NYSE:GKOS) Holdings Lifted by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D grew its position in Glaukos Co. (NYSE:GKOS) by 26.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 41,883 shares of the medical instruments supplier’s stock after purchasing an additional 8,884 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.09% of Glaukos worth $3,329,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of GKOS. GAMMA Investing LLC bought a new position in Glaukos in the 4th quarter worth about $55,000. CWM LLC increased its stake in shares of Glaukos by 309.5% during the third quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after acquiring an additional 1,046 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Glaukos by 17.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $137,000 after acquiring an additional 270 shares during the period. Mackenzie Financial Corp acquired a new position in shares of Glaukos during the third quarter valued at approximately $203,000. Finally, Xponance Inc. acquired a new position in shares of Glaukos during the third quarter valued at approximately $208,000. Institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on GKOS shares. Citigroup raised their price objective on shares of Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 25th. Mizuho raised their price objective on shares of Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Needham & Company LLC raised their price objective on shares of Glaukos from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Truist Financial reiterated a “buy” rating and set a $110.00 price objective on shares of Glaukos in a research note on Monday, April 8th. Finally, Wells Fargo & Company raised their target price on shares of Glaukos from $83.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.80.

Glaukos Trading Down 0.6 %

Glaukos stock opened at $99.48 on Friday. The company has a 50 day moving average price of $92.42 and a 200 day moving average price of $81.74. Glaukos Co. has a 52 week low of $45.38 and a 52 week high of $103.66. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34. The firm has a market capitalization of $4.99 billion, a price-to-earnings ratio of -35.78 and a beta of 1.08.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The firm had revenue of $82.40 million during the quarter, compared to analyst estimates of $81.00 million. During the same period in the prior year, the business posted ($0.53) EPS. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. Research analysts forecast that Glaukos Co. will post -2.18 EPS for the current year.

Insiders Place Their Bets

In other Glaukos news, COO Joseph E. Gilliam sold 59,801 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $100.47, for a total value of $6,008,206.47. Following the completion of the sale, the chief operating officer now owns 101,845 shares in the company, valued at approximately $10,232,367.15. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Alex R. Thurman sold 1,372 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $100.54, for a total transaction of $137,940.88. Following the transaction, the chief financial officer now owns 52,532 shares in the company, valued at approximately $5,281,567.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joseph E. Gilliam sold 59,801 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $100.47, for a total transaction of $6,008,206.47. Following the transaction, the chief operating officer now owns 101,845 shares in the company, valued at approximately $10,232,367.15. The disclosure for this sale can be found here. Insiders sold a total of 242,357 shares of company stock worth $22,857,372 in the last quarter. 6.40% of the stock is currently owned by corporate insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.